The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer

PURPOSE: Activation of the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway has been implicated in anti-estrogen resistance in breast cancer. We tested the therapeutic potential of the novel PI3K/mTOR dual inhibitor P7170 in a panel of anti-estrogen-sensitive and -resistant models of ER+ breast...

詳細記述

保存先:
書誌詳細
出版年:Breast Cancer Res Treat
主要な著者: Bean, Jennifer R., Hosford, Sarah R., Symonds, Lynn K., Owens, Philip, Dillon, Lloye M., Yang, Wei, Shee, Kevin, Schwartz, Gary N., Marotti, Jonathan D., Muller, Kristen E., Rosenkranz, Kari M., Barth, Richard J., Chen, Vivian S., Agarwal, Veena R., Miller, Todd W.
フォーマット: Artigo
言語:Inglês
出版事項: 2014
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4302040/
https://ncbi.nlm.nih.gov/pubmed/25491778
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-014-3201-6
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料